Just two years ago, Dendreon Corp. found itself in the hot seat as payors and physicians questioned the high price of its prostate cancer immunotherapy Provenge (sipuleucel-T). The therapy launched in April 2010 at $93,000 for a three-course treatment, (SeeAlso see "Dendreon Set To Ship Provenge Within A Week" - Pink Sheet, 29 April, 2010.) and its eventual acceptance paved the way for a higher price ceiling for cancer drugs.
Ten thousand dollars per month for new oncology drugs has become just about standard, and the trend is not likely...